Walker-256 (LLC-WRC 256) Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Rat cell lines

Organism

Rat

Donor History

Adenocarcinoma of the rat mammary gland

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% heat-inactivated FBS

,

0.01 mg/mL Insulin

,

4.5 g/L glucose

,

1 mM Sodium pyruvate and 10 mM HEPES. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/Walker-256-LLC-WRC-256-Cells/500375

SKU: 500375 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The Walker-256 cell line is a rat carcinoma cell line that is widely used in cancer research, specifically in the study of tumor biology and chemotherapy. Originating from a mammary gland carcinoma of a rat, this cell line is particularly noted for its aggressive metastatic behavior, making it a valuable model for studying cancer progression and metastasis. It has been used extensively to investigate the mechanisms of tumor growth and the efficacy of anti-cancer drugs in vivo.

Walker-256 cells are adaptable to various environments, allowing them to be grown in a number of different animal models, which helps in the study of cancer biology in a systemic context. This cell line is instrumental in pharmacological studies, particularly those related to the development and testing of new chemotherapy agents. Researchers use Walker-256 to assess drug-induced cytotoxicity and to explore the potential mechanisms of action of novel therapeutic compounds. Its robust use in research provides critical insights into the dynamics of tumor growth and the systemic effects of tumors on host physiology.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.